International Journal of Pharmaceutics & Drug Research

Prachi Gupta*, Mr. Muraree Lal, Dr. Avinash Krishnrao Kondalkar

ABSTRACT

Rheumatoid arthritis (RA) is a symmetrical, chronic inflammatory autoimmune disease that first affects the small joints before spreading to the larger joints, skin, eyes, heart, kidneys, and lungs. Niosomes are non-ionic surfactants with multilamellar vesicles that release the medicine through their bilayer in a regulated manner, allowing for continuous release of the contained substance. Therefore, the purpose of this study is to develop and assess a Flufenamic niosomal gel for the treatment of rheumatoid arthritis. Results showed that the F9 formulation of niosome observed to have average particle size of 155.25 while the % entrapment efficiency was found to be 76.65 %. The Zeta Potential (mV) of F9 formulation was noticed to -39.74. The formulated niosomal gel was observed to have drug content of 99.12±0.15. The pH of gel was within the range of skin pH which is 6.85±0.02. The Extrudability (g) & Spreadibility (g.cm/sec) was found to be 165±6 and 11.35±0.85 respectively. The viscosity was observed to be 3465±15 cps. In-vitro drug release study of prepared gel formulation indicated at 12 hours the % cumulative drug release was 98.85 %. The formulated niosomal gel was observed too be stable for 3 months at 4.0±0.2°C. In conclusion, this study suggests that transdermal formulations of in Flufenamic niosomal gel were successfully developed and could be used as an alternative route of administration.

[Full Text Article]